. Absorption titration of derivative 3b (50 µM) with increasing concentrations of ctDNA.
[DNA] = 0, 10, 20, 40, 60, 80, 100 and 120 µM. Inset: corresponding to the plot of [DNA]/(εa − εf) as function of DNA concentration as determined from the absorption spectral data. Arrow (↑) refers to hyperchromic effect. [DNA] = 0 (gray), 0 (black), 20 (red), 40 (green), 60 (yellow), 80 (dark blue), 100 (pink) and 120 (light blue). Arrow (↓) refers to hypochromic effect. Figure S39 . Antiproliferative activity of 3b against nine cancerous cell lines: U251 (glioma, SNC); MCF-7 (breast adenocarcinoma); NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-0 (kidney); NCI-H460 (lung non-small cell adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon); K-562 (Chronic myeloid leukemia) and human keratinocytes (HaCaT). Figure S40 . Antiproliferative activity of 3c against nine cancerous cell lines: U251 (glioma, SNC); MCF-7 (breast adenocarcinoma); NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-0 (kidney); NCI-H460 (lung non-small cell adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon); K-562 (Chronic myeloid leukemia) and human keratinocytes (HaCaT).
S28

Figure S41
. Antiproliferative activity of 3d against nine cancerous cell lines: U251 (glioma, SNC); MCF-7 (breast adenocarcinoma); NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-0 (kidney); NCI-H460 (lung non-small cell adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon); K-562 (Chronic myeloid leukemia) and human keratinocytes (HaCaT). Figure S42 . Antiproliferative activity of 3e against nine cancerous cell lines: U251 (glioma, SNC); MCF-7 (breast adenocarcinoma); NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-0 (kidney); NCI-H460 (lung non-small cell adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon); K-562 (Chronic myeloid leukemia) and human keratinocytes (HaCaT).
Figure S43
. Antiproliferative activity of 3f against nine cancerous cell lines: U251 (glioma, SNC); MCF-7 (breast adenocarcinoma); NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-0 (kidney); NCI-H460 (lung non-small cell adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon); K-562 (Chronic myeloid leukemia) and human keratinocytes (HaCaT).
Figure S44
. Antiproliferative activity of 3g against nine cancerous cell lines: U251 (glioma, SNC); MCF-7 (breast adenocarcinoma); NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-0 (kidney); NCI-H460 (lung non-small cell adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon); K-562 (Chronic myeloid leukemia) and human keratinocytes (HaCaT).
Figure S45
. Antiproliferative activity of 3h against nine cancerous cell lines: U251 (glioma, SNC); MCF-7 (breast adenocarcinoma); NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-0 (kidney); NCI-H460 (lung non-small cell adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon); K-562 (Chronic myeloid leukemia) and human keratinocytes (HaCaT). Table S1 . Cell lines used in vitro antiproliferative assays and their inoculation densities.
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